市场调查报告书
商品编码
1370609
抗生素抗药性市场依疾病(cUTI、cIAI、BSI)、病原体(大肠桿菌、肺炎克雷伯菌)、药物类别(噁唑烷酮类、头孢菌素)、作用机转(细胞壁、蛋白质合成抑制剂)、配销通路、全球预测, 2023-2032Antibiotic Resistance Market-By Disease (cUTI, cIAI, BSI), Pathogen (E. coli, K. pneumoniae), Drug Class (Oxazolidinones, Cephalosporin), Mechanism of Action (Cell Wall, Protein Synthesis Inhibitors), Distribution Channel, Global Forecast, 2023-2032 |
2023年至2032年,抗生素抗药性市场将以5.3%的复合年增长率成长。滥用抗生素药物引发的抗药性细菌的发展正在增加对替代治疗方案的需求,推动产业扩张。
此外,全球人口老化,对感染的敏感度更高,正在推动对新型抗生素的需求。医疗保健相关感染的增加和多重抗药性病原体的出现也推动了对新型抗菌药物研发的投资,以对抗抗生素抗药性。
政府措施、监管激励措施以及对抗生素抗药性威胁的认识的提高将进一步促进市场扩张。 2022 年11 月,联合国粮农组织、环境署、世界动物卫生组织和世界卫生组织宣布了一项名为「抗菌素抗药性多利益攸关方伙伴关係平台」的新倡议,以解决抗菌素抗药性对全球人口日益严重的影响。鑑于对创新解决方案的迫切需求,抗生素抗药性产业将在未来几年大幅扩张。
市场根据疾病、病原体、药物类别、作用机制、配销通路和地区进行划分。
根据疾病情况,从2023 年到2032 年,血流感染领域的复合年增长率将达到5%。败血症和血流感染盛行率的不断上升、医疗保健相关病例的增加以及重症监护环境中抗生素耐药病原体日益严峻的挑战将推动成长在段中。
到 2032 年,铜绿假单胞菌病原体部分的复合年增长率将达到 6.5%,这是由病原体对多种抗生素的广泛抗药性等因素推动的,这推动了对替代治疗的需求。医疗机构中铜绿假单胞菌感染发生率的上升也将促进该领域的成长。
由于头孢菌素抗药性菌株的盛行率不断上升,头孢菌素药物类别在 2023 年至 2032 年间将呈现 6.1% 的复合年增长率,这将需要开发新的有效治疗方法。医疗保健相关感染负担的不断增加以及对创新抗菌药物的需求也将促进该领域的成长。
从地区来看,到 2032 年,亚太地区抗生素抗药性产业的复合年增长率将达到 5.8%,受到该地区医疗保健普及、人口密度和抗菌药物滥用等因素的推动。随着该地区应对抗生素抗药性挑战,意识的提高、政府措施和经济发展将进一步推动产业扩张。
The antibiotic resistance market will grow with 5.3% CAGR from 2023 to 2032. The development of drug-resistant bacteria triggered by misuse of antibiotic medications is increasing the demand for alternative treatment options, propelling industry expansion.
Additionally, the aging global population, with a higher susceptibility to infections, is driving the need for novel antibiotics. Rising healthcare-associated infections and the emergence of multi-drug-resistant pathogens have also fueled investments in research and development of new antimicrobial agents to combat antibiotic resistance.
Government initiatives, regulatory incentives, and increased awareness about the threat of antibiotic resistance will further contribute to market expansion. In November 2022, the UN's FAO, UNEP, the World Organization for Animal Health, and the WHO announced a new initiative called the Antimicrobial Resistance Multi-Stakeholder Partnership Platform to address the escalating implications of antimicrobial resistance on the global population. Given the pressing need for innovative solutions, the antibiotic resistance industry will expand significantly in the coming years.
The market is segregated based on disease, pathogen, drug class, mechanism of action, distribution channel, and region.
Based on disease, the bloodstream infection segment will exhibit a 5% CAGR from 2023 to 2032. The increasing prevalence of sepsis and bloodstream infections, rising healthcare-associated cases, and the growing challenge of antibiotic-resistant pathogens in critical care settings will drive growth in the segment.
The P. aeruginosa pathogen segment will reflect a 6.5% CAGR through 2032, driven by factors such as the pathogen's widespread resistance to multiple antibiotics, which is driving the demand for alternative treatments. The rising incidences of P. aeruginosa infections in healthcare settings will also foster growth in the segment.
The cephalosporin drug class segment will exhibit 6.1% CAGR between 2023 and 2032, driven by the escalating prevalence of cephalosporin-resistant bacterial strains, which will necessitate the development of new and effective treatments. The rising burden of healthcare-associated infections and demand for innovative antimicrobial agents will also augment growth in the segment.
Regionally, the Asia Pacific antibiotic resistance industry will witness a 5.8% CAGR through 2032, driven by factors such as increasing healthcare access, population density, and antimicrobial misuse in the region. Rising awareness, government initiatives, and economic development will further drive industry expansion as the region addresses antibiotic resistance challenges.